Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2022 06:45 ET | Source: Cingulate Inc.

Cingulate to Present at Aegis Virtual Conference

KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
February 08, 2022 06:45 ET | Source: Cingulate Inc.

Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
January 25, 2022 06:45 ET | Source: Cingulate Inc.

Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors

KANSAS CITY, Kan., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Following its initial public offering last month, Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its...
December 10, 2021 11:00 ET | Source: Cingulate Inc.

Cingulate Inc. Announces Closing of Initial Public Offering

KANSAS CITY, Kan., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™...
December 07, 2021 21:05 ET | Source: Cingulate Therapeutics LLC

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering

KANSAS CITY, Kan., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™...